

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10814160
Filing Date	2004-04-01
First Named Inventor	David WALLACH
Art Unit	1643
Examiner Name	S. Rawlings
Attorney Docket Number	WALLACH26A

U.S.PATENTS**Remove**

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add**U.S.PATENT APPLICATION PUBLICATIONS****Remove**

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add**FOREIGN PATENT DOCUMENTS****Remove**


Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button


Add**NON-PATENT LITERATURE DOCUMENTS****Remove**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10814160
	Filing Date	2004-04-01
	First Named Inventor	David WALLACH
	Art Unit	1643
	Examiner Name	S. Rawlings
	Attorney Docket Number	WALLACH26A

SR	1	WEIDANZ et al, "N-acetylglucosamine kinase and N-acetylglucosamine 6-phosphate deacetylase in normal human erythrocytes and Plasmodium falciparum," Br J Haematol 95(4):645-653 (1996)	<input type="checkbox"/>
EXAMINER SIGNATURE			
Examiner Signature			Date Considered 9/19/07
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP-901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.</p>			

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				Filing Date	Even Date Herewith
				First Named Inventor	David WALLACH
				Group Art Unit	1642
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	WALLACH-26A
Sheet	1	of	4		

Examiner Signature		Date Considered	9/19/07
--------------------	---	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
(use as many sheets as necessary)				Filing Date	Even Date Herewith
				First Named Inventor	David WALLACH
				Group Art Unit	1642
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	WALLACH=26A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
SN	AG	Bertin et al, "Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis", <u>Proc Natl Acad Sci</u> 94(4):1172-1176 (1997)				
	AH	Bowie et al, "Deciphering the message in protein sequences: tolerance to amino acid substitutions", <u>Science</u> 247(4948):1306-1310 (1990)				
	AI	Burgess et al, "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue", <u>J Cell Biol</u> 111(5 Pt 1):2129-2138 (1990)				
	AJ	Chou et al, "Prediction of the tertiary structure and substrate binding site of caspase-8" <u>FEBS Lett</u> 419(1):49-54 (1997)				
	AK	Frank AW, "Synthesis and properties of N-, O-, and S-phospho derivatives of amino acids, peptides, and proteins", <u>CRC Crit Rev Biochem</u> 16(1):51-101 (1984)				
	AL	GIBSON et al, "Homology between two EBV early genes and HSV ribonucleotide reductase and 38K genes", <u>Nucleic Acids Res</u> 12(12):5087-5099 (1984)				
	AM	HAN et al, "MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclX _L and initiates cell death", <u>Proc Natl Acad Sci</u> 94(21):11333-11338 (1997)				
	AN	Hu et al, "A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis", <u>J Biol Chem</u> 272(15):9621-9624 (1997)				
	AO	IIZUKA et al, "Enhanced expression of nucleobindin in lymphatic organs of lupus-prone mice", <u>Lupus</u> 6(4):365-370 (1997)				
	AP	ISHIKAWA et al, "Prediction of the coding sequences of unidentified human genes. VIII. 78 new cDNA clones from brain which code for large proteins in vitro", <u>DNA Res</u> 4(5):307-313 (1997)				
	AQ	ISHIKAWA et al, "Prediction of the coding sequences of unidentified human genes. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro", <u>DNA Res</u> 5(3):169-176 (1998)				
	AR	KAMADA et al, "A cloning method for caspase substrates that uses the yeast two-hybrid system: cloning of the antiapoptotic gene gelsolin", <u>Proc Natl Acad Sci USA</u> 95(15):8532-8537 (1998)				

Examiner Signature	1	Date Considered	9/19/07
--------------------	---	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	
				Filing Date	Even Date Herewith
				First Named Inventor	David WALLACH
				Group Art Unit	1642
				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	WALLACH-26A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
SYR	AS	KAMINE et al, "Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator", <u>Virology</u> 216(2):357-366 (1996)			
	AT	KOSEKI et al., "ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases", <u>Proc Natl Acad Sci</u> 95(9):5156-5160 (1998)			
	AU	LAZAR et al, "Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities", <u>Mol Cell Biol</u> 8(3):1247-1252 (1988)			
	AV	MEDEMA et al "FLICE is activated by association with the CD95 death-inducing signaling complex (DISC)", <u>EMBO J</u> 16(10):2794-2804 (1997)			
	AW	MEDINA et al, "Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway", <u>Cancer Res</u> 57(17):3697-3707 (1997)			
	AX	MIURA et al, "Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure", <u>Biochem Biophys Res Commun</u> 187(1):375-380 (1992)			
	AY	MIURA et al, JP 06 025292, "Protein and its Gene" (February 1, 1994) Abstract Only (Database WPI: Section Ch, Week 199410 (Derwent Publications))			
	AZ	MUZIO et al, "FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens", <u>J Biol Chem</u> 272(5):2952-2956 (1997)			
	BA	SCAFFIDI et al "FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b, <u>J Biol Chem</u> 272(43):26953-26958 (1997)			
	BB	SCANLAN et al, "Characterization of human colon cancer antigens recognized by autologous antibodies", <u>Intl J Cancer</u> 76(5):652-658 (1998)			
	BC	TAKAHASHI et al, "Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase-8", <u>Oncogene</u> 14(23):2741-2752 (1997)			
✓	BD	WRIGHT et al, "A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts", <u>Exp Cell Res</u> 222(1):54-60 (1996)			

Examiner Signature	1 ~	Date Considered	9/19/07
--------------------	-----	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
(use as many sheets as necessary)				Filing Date	Even Date Herewith
Sheet	4	of	4	First Named Inventor	David WALLACH
				Group Art Unit	1642
				Examiner Name	
				Attorney Docket Number	WALLACH=26A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
SZ	BE	Accession V01555, Farrell P, "Epstein-Barr virus (EBV) genome, strain 895-8" (December 6, 1983) (GENEMBL 'Online!')			
	BI	Accession C18037, Fujiwara T, "Human placenta cDNA 5'-end GEN-556E08" (October 4, 1996) (GENEMBL 'Online!')			
	BG	Accession H23509, Hillier et al, "ym53a01.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:51785 3' similar to ti gb:M64992 proteasome component C2 (human), mRNA sequence" (July 8, 1995) (GENEMBL 'Online!')			
	BJ	Accession AA608733, Hillier et al, "ae56f06.s1 Stratagene lung carcinoma 937218 homo sapiens cDNA clone IMAGE:950915 3' similar to TR:61224066 ORF2: Function unknown" (October 1, 1997) (GENEMBL 'Online!')			
	BF	Accession M96824, Miura et al, "Human nucleobindin precursor" (November 19, 1992) (GENEMBL 'Online!')			
	BK	Accession AB006626, O'Hara et al, "Homo sapiens mRNA for KIAA0288 protein, partial cds" (October 31, 1997) (GENEMBL 'Online!')			
	BL	Accession AB007870, O'Hara O, "Homo sapiens KIAA0419 mRNA complete cds" (December 5, 1997) (GENEMBL 'Online!')			
	BN	Accession AB014515, O'Hara et al, "Homo sapiens mRNA for KIAA0615 protein, complete cds" (July 15, 1998) (GENEMBL 'Online!')			
	BH	Accession U49973, Robertson HM, "ORF2 associated to human trigger 1 transposable element" (March 14, 1996) (GENEMBL 'Online!')			
	BP	Accession U67734, Sheridan et al, "Human cPLA2 interacting protein mRNA, complete cds" (January 6, 1999) (GENEMBL 'Online!')			
	BM	Accession AA746639, Strausberg R, "nx27c04.s1 NCI_CGAP_GC4 Homo sapiens cDNA clone IMAGE:1257318 3' similar to WP:F59B2.3 CE00231 N-acetyl-glucosamine-6-phosphate deacetylase, mRNA sequence" (January 19, 1998) (GENEMBL 'Online!')			
↓	BO	Accession AC004466, Worley et al, "Homo sapiens 12q13.1 PAC RPCI5-1057120 (Roswell Park Cancer Institute Human PAC library), Version AC004466.1; GI:3617739; September 17, 1998 (NCBI)			

Examiner Signature	1	Date Considered	9/19/07
--------------------	---	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.